Table 1 Baseline Patient and Disease Characteristics and Best Responses after Low-Dose RT
ID # | Age | Sex | Histology | IO Agent | High-Dose RT Site | High Dose RT, (Gy/fx) | Low-Dose Site | Low-Dose Type | Mean Low-Dose (Gy/fx) | Time between RT & IO | Time to Response to RT, days | Low-Dose Lesions, no. | Low-Dose Lesion Response, %* | No-Dose Lesions, no. | No-Dose Lesion Response, %* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 91 | M | Adenocarcinoma | Pembrolizumab | Lung | 45/15 | Lung | Scatter | 18.92/15 | 0 | 42 | 1 | −100% | 2 | 8% |
2 | 52 | M | Adenocarcinoma | Pembrolizumab | Lung | 50/4 | Lung | Scatter | 2.45/4 | 52 | 26 | 1 | −19% | 2 | −30% |
3 | 69 | M | SCC | Ipilimumab | Lung | 50/4 | Lung | Scatter | 6.49/4 | 32 | 54 | 3 | −100% | 1 | −22% |
4 | 21 | F | HCC | Ipilimumab | Lung | 50/4 | Lung | Scatter | 3.05/4 | 39 | 21 | 1 | −65% | 5 | −38% |
5 | 73 | F | Adenocarcinoma | Ipilimumab | Lung | 50/4 | Lung | Scatter | 2.47/4 | 27 | 42 | 1 | −21% | 1 | −2% |
6 | 67 | F | Adenocarcinoma | Ipilimumab | Liver | 50/4 | Liver | Scatter | 6.43/4 | 1 | 38 | 1 | −59% | 0 | – |
7 | 63 | M | Adenocarcinoma | Ipilimumab | Liver | 50/4 | Liver | Scatter | 9.32/4 | 1 | 35 | 1 | −47% | 1 | −45% |
8 | 60 | M | Adenocarcinoma | Ipilimumab | Liver | 50/4 | Lung | Scatter | 24.11/4 | 25 | 39 | 1 | −63% | 3 | 7% |
9 | 49 | F | ACC | Pembrolizumab | Lung | 50/4 | Lung | Scatter | 12.03/4 | 39 | 38 | 2 | −6% | 1 | −4% |
10 | 53 | F | Adenocarcinoma | Ipilimumab | Lung | 50/4 | Lung | Scatter | 4.01/4 | 27 | 23 | 1 | − 35% | 2 | −23% |
11 | 44 | M | ACC | Ipilimumab | Lung | 50/4 | Lung | Scatter | 5.14/4 | 37 | 43 | 2 | −43% | 2 | −33% |
12 | 65 | M | CRC | Ipilimumab | Lung | 50/4 | Lung | Scatter | 19.43/4 | 29 | 10 | 2 | −41% | 4 | 44% |
13 | 43 | M | RCC | Ipilimumab | Lung | 50/4 | Liver | Scatter | 14.4/4 | 1 | 45 | 1 | −53% | 5 | −41% |
14 | 56 | M | Neuroendocrine | Ipilimumab | Liver | 50/4 | Liver | Scatter | 15.5/4 | 26 | 153 | 3 | −11% | 3 | 10% |
15 | 59 | M | ACC | Ipilimumab | Liver | 50/4 | Liver | Scatter | 21.8/4 | 22 | 12 | 3 | −5% | 3 | −7% |
16 | 74 | M | Adenocarcinoma | Ipilimumab | Lung | 50/4 | Abdomen | Scatter | 6.27/4 | 1 | 40 | 1 | −36% | 1 | 14% |
17 | 62 | F | Adenocarcinoma | Ipilimumab | Lung | 50/4 | Lung | Scatter | 6.06/4 | 96 | 38 | 1 | −42% | 2 | −55% |
18 | 71 | M | Adenocarcinoma | Pembrolizumab | Lung | 50/4 | Lung | Scatter | 12.97/4 | 105 | 81 | 1 | −100% | 1 | 53% |
19 | 49 | M | DLBCL | Pembrolizumab | Inguinal | 50/20 | Inguinal | Scatter | 4.74/20 | 31 | 70 | 1 | −100% | 1 | −4% |
20 | 53 | M | Adenocarcinoma | Pembrolizumab | Lung | 45/15 | Lung | Scatter | 12.20/15 | 74 | 114 | 1 | −42% | 0 | – |
21 | 53 | M | SCC | Pembrolizumab | Lung | 50/4 | Abdomen | Intentional | 8/4 | 39 | 109 | 1 | −25% | 1 | −56% |
22 | 65 | F | Adenocarcinoma | Pembrolizumab | Lung | 52.5/15 | Lung | Intentional | 7.5/5 | 27 | 119 | 2 | −67% | 1 | 64% |
23 | 69 | M | MCC | Atezolizumab | Adrenal | 70/10 | Inguinal | Intentional | 6/6 | 27 | 19 | 2 | −32% | 0 | – |
24 | 80 | M | SCC | Nivolizumab | Lung | 52.5/15 | Lung | Intentional | 6/6 | 26 | 67 | 1 | −11% | 0 | – |
25 | 56 | F | Melanoma | Ipilimumab | Spleen | 25/5 | Liver | Intentional | 7.5/5 | 1 | 29 | 2 | −7% | 2 | 22% |
26 | 69 | F | Adenocarcinoma | Atezolizumab | Liver | 60/10 | Abdomen | Intentional | 8/4 | 1 | 39 | 1 | −7% | 1 | 0% |